Payment overview · 2025
General Payments
$2,638.78
117 reported records · 20 companies
Healthcare provider profile · identity verified
Li Yang, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · BROOKLYN, NY · NPI 1598035081
Verified facts
What the public records show
CMS Open Payments records show Li Yang, MD received $2,638.78 in general payments during 2025 across 117 reported records.
Travere Therapeutics, Inc. accounted for 11.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Kerendia, Lokelma, Nexletol, Rayaldee, Tarpeyo, Velphoro, Veltassa.
AKEBIA THERAPEUTICS INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auryxia as an associated drug or biological on 494 records involving 327 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Auryxia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 380 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Jardiance by this doctor in 2024.
Calliditas Therapeutics US Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TARPEYO as an associated drug or biological on 14378 records involving 5162 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Tarpeyo by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Nexletol by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Nexlizet by this doctor in 2024.
Fresenius USA Marketing, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VELPHORO as an associated drug or biological on 8763 records involving 2642 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Velphoro by this doctor in 2024.
OPKO Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RAYALDEE as an associated drug or biological on 5435 records involving 1739 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Rayaldee by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Gemtesa by this doctor in 2024.
Vifor Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veltassa as an associated drug or biological on 5970 records involving 2480 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Veltassa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $300.41 | 11.4% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $288.02 | 10.9% | 14 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $286.05 | 10.8% | 13 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $228.47 | 8.7% | 10 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $220.65 | 8.4% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $158.60 | 6.0% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $141.11 | 5.3% | 6 | 2025 |
| AKEBIA THERAPEUTICS INC | Unresolved — no canonical attribution shown | $135.42 | 5.1% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $115.86 | 4.4% | 6 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $109.88 | 4.2% | 6 | 2025 |
| Fresenius USA Marketing, Inc. | Unresolved — no canonical attribution shown | $108.11 | 4.1% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $105.86 | 4.0% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $86.04 | 3.3% | 4 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $85.37 | 3.2% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $74.10 | 2.8% | 3 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $67.54 | 2.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.57 | 1.9% | 2 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $38.40 | 1.5% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.83 | 0.8% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $17.49 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,528.90 | 111 |
| Education | $109.88 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $286.05 | 13 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $228.47 | 10 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $220.65 | 11 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $158.60 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $141.11 | 6 | 2025 |
Source payment records
|
|||||
| Vafseo Normalized: vafseo |
Drug | AKEBIA THERAPEUTICS INC | $135.42 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $134.37 | 7 | 2025 |
Source payment records
|
|||||
| Filspari Normalized: filspari |
Drug | Travere Therapeutics, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $109.88 | 6 | 2025 |
Source payment records
|
|||||
| VELPHORO Normalized: velphoro |
Drug | Fresenius USA Marketing, Inc. | $108.11 | 5 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $106.51 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $105.86 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $86.04 | 4 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $85.37 | 4 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $76.31 | 4 | 2025 |
Source payment records
|
|||||
| Vanrafia Normalized: vanrafia |
Drug | Novartis Pharmaceuticals Corporation | $76.31 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $74.64 | 4 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $74.10 | 3 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $50.57 | 2 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $38.40 | 2 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $25.63 | 1 | 2025 |
Source payment records
|
|||||
| VOYXACT Normalized: voyxact |
Drug | Otsuka Pharmaceutical Development & Commercialization, Inc. | $23.95 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $17.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 53 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 185 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 136 | exact normalized | Medicare Part D |
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 31 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 76 | exact normalized | Medicare Part D |
| RAYALDEE rayaldee |
2025 | Rayaldee | 2024 | 127 | exact normalized | Medicare Part D |
| TARPEYO tarpeyo |
2025 | Tarpeyo | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VELPHORO velphoro |
2025 | Velphoro | 2024 | 144 | exact normalized | Medicare Part D |
| Veltassa veltassa |
2025 | Veltassa | 2024 | 63 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AKEBIA THERAPEUTICS INC Exact reporting entity; no affiliate inference |
2025 | Auryxia open payments reported associated product |
CMS Open Payments — General Payments 494 supporting records · 327 recipient NPIs · example record 1241812131 |
Auryxia · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
380 | 69 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
31 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
136 | 25 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
185 | 39 |
| Calliditas Therapeutics US Inc. Exact reporting entity; no affiliate inference |
2025 | TARPEYO open payments reported associated product |
CMS Open Payments — General Payments 14378 supporting records · 5162 recipient NPIs · example record 1234989331 |
Tarpeyo · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
76 | 11 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Fresenius USA Marketing, Inc. Exact reporting entity; no affiliate inference |
2025 | VELPHORO open payments reported associated product |
CMS Open Payments — General Payments 8763 supporting records · 2642 recipient NPIs · example record 1244803773 |
Velphoro · 2024 Exact normalized brand match · 1 Part D row |
144 | 25 |
| OPKO Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | RAYALDEE open payments reported associated product |
CMS Open Payments — General Payments 5435 supporting records · 1739 recipient NPIs · example record 1222072234 |
Rayaldee · 2024 Exact normalized brand match · 1 Part D row |
127 | 17 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
53 | 16 |
| Vifor Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | Veltassa open payments reported associated product |
CMS Open Payments — General Payments 5970 supporting records · 2480 recipient NPIs · example record 1172020739 |
Veltassa · 2024 Exact normalized brand match · 1 Part D row |
63 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Vascepa | Icosapent Ethyl | 731 | 107 |
| Amlodipine Besylate | Amlodipine Besylate | 505 | 98 |
| Tamsulosin Hcl | Tamsulosin Hcl | 505 | 79 |
| Losartan Potassium | Losartan Potassium | 454 | 90 |
| Allopurinol | Allopurinol | 432 | 59 |
| Finasteride | Finasteride | 422 | 67 |
| Farxiga | Dapagliflozin Propanediol | 380 | 69 |
| Nifedipine Er | Nifedipine | 314 | 46 |
| Sevelamer Carbonate | Sevelamer Carbonate | 312 | 47 |
| Hydralazine Hcl | Hydralazine Hcl | 288 | 44 |
| Labetalol Hcl | Labetalol Hcl | 274 | 42 |
| Acarbose | Acarbose | 264 | 39 |
| Tradjenta | Linagliptin | 253 | 49 |
| Retacrit | Epoetin Alfa-Epbx | 237 | 41 |
| Glipizide Er | Glipizide | 225 | 33 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 213 | 36 |
| Gabapentin | Gabapentin | 198 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 193 | 35 |
| Potassium Citrate Er | Potassium Citrate | 187 | 29 |
| Jardiance | Empagliflozin | 185 | 39 |
| Atorvastatin Calcium | Atorvastatin Calcium | 183 | 33 |
| Calcitriol | Calcitriol | 179 | 29 |
| Calcium Acetate | Calcium Acetate | 146 | 22 |
| Velphoro | Sucroferric Oxyhydroxide | 144 | 25 |
| Myrbetriq | Mirabegron | 141 | 24 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 137 | 20 |
| Kerendia | Finerenone | 136 | 25 |
| Januvia | Sitagliptin Phosphate | 132 | 18 |
| Rayaldee | Calcifediol | 127 | 17 |
| Furosemide | Furosemide | 121 | 35 |
| Famotidine | Famotidine | 107 | 20 |
| Colchicine | Colchicine | 102 | 20 |
| Levothyroxine Sodium | Levothyroxine Sodium | 101 | 14 |
| Prednisone | Prednisone | 100 | 18 |
| Irbesartan | Irbesartan | 88 | 11 |
| Spironolactone | Spironolactone | 85 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 83 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 76 | 12 |
| Nexletol | Bempedoic Acid | 76 | 11 |
| Linzess | Linaclotide | 71 | 12 |
| Rybelsus | Semaglutide | 71 | 16 |
| Dutasteride | Dutasteride | 69 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 63 | 14 |
| Ozempic | Semaglutide | 61 | suppressed |
| Atenolol | Atenolol | 60 | suppressed |
| Carvedilol | Carvedilol | 60 | suppressed |
| Repaglinide | Repaglinide | 59 | 18 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 55 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 54 | 20 |
| Tacrolimus | Tacrolimus | 54 | suppressed |
| Gemtesa | Vibegron | 53 | 16 |
| Simvastatin | Simvastatin | 52 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 50 | suppressed |
| Xphozah | Tenapanor Hcl | 47 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 45 | 24 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 44 | suppressed |
| Tarpeyo | Budesonide | 43 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Lisinopril | Lisinopril | 39 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 38 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 37 | suppressed |
| Silodosin | Silodosin | 35 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 31 | 12 |
| Gentamicin Sulfate | Gentamicin Sulfate | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Metformin Hcl | Metformin Hcl | 27 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 27 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Folic Acid | Folic Acid | 25 | suppressed |
| Lidocaine | Lidocaine | 25 | suppressed |
| Auryxia | Ferric Citrate | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Omeprazole | Omeprazole | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 19 |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 20 | suppressed |
| Prograf | Tacrolimus | 20 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 14 | suppressed |
| Nateglinide | Nateglinide | 14 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 14 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 11 | suppressed |
| Entecavir | Entecavir | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Zafirlukast | Zafirlukast | 11 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,638.78 · 117 records | Travere Therapeutics, Inc. | ACCRUFER, BENLYSTA, Fabhalta, Filspari, GEMTESA, IBSRELA, JARDIANCE, JYNARQUE, KRYSTEXXA, Kerendia, LOKELMA, LUPKYNIS, NEXLETOL, OTEZLA, RAYALDEE, REPATHA, TARPEYO, TAVNEOS, VELPHORO, VERQUVO, VOYXACT, Vafseo, Vanrafia, Veltassa | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AKEBIA THERAPEUTICS INC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error